CompletedNCT05895643
Semaglutide and alcohol use with co-occurring obesity
About this title
Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?
Read the official source — NCT05895643Medication studyAges 18–70DenmarkAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 70 years.
- Listed locations
- FrederiksbergSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: June 13, 2023
- Recruitment status
- Completed
- Enrollment listed in the registry
- 108
- Sponsor
- Psychiatric Centre Rigshospitalet
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Denmark
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT05895643
- Official title
Show the full official title
Does the Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Frederiksberg
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Psychiatric Centre Rigshospitalet.
Did this study involve medication?
Yes. The study involved medication, including Semaglutide Injectable Product and Placebo.
Who was this study for?
Listed age limits: 18 years to 70 years.
